Vaishali Parab

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

I. Wistuba, J. Zha, L. Rangell, 2014, Clinical Cancer Research.

HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors

G. Hampton, P. Hegde, M. Merchant, 2013, Molecular Cancer Therapeutics.

Companion Diagnostics & Cancer Biomarkers HGFasaCirculatingBiomarker ofOnartuzumabTreatment in Patients with Advanced Solid Tumors

G. Hampton, P. Hegde, M. Merchant, 2013 .

HGFasaCirculatingBiomarkerofOnartuzumabTreatmentin Patients with Advanced Solid Tumors

G. Hampton, P. Hegde, M. Merchant, 2013 .

HGFasaCirculatingBiomarker ofOnartuzumabTreatment in Patients with Advanced Solid Tumors

G. Hampton, P. Hegde, M. Merchant, 2013 .

Fit-for-purpose biomarker immunoassay qualification and validation: three case studies.

Melissa Cheu, Alyssa Morimoto, Kyra Cowan, 2016, Bioanalysis.